Articles

The hypoxia-inducible factor-2α inhibitor belzutifan had antitumor activity in treatment-naïve and pretreated disease. Read More ›

In a phase 2 trial, atezolizumab plus bevacizumab showed promise after disease progression on monotherapy with atezolizumab or sunitinib. Read More ›

In a phase 1b/2 study, lenvatinib plus pembrolizumab combination showed promise as first-line therapy and beyond. Read More ›

Compared with sorafenib, tivozanib was associated with longer progression-free survival, higher rates of response, and better tolerability in the third-line setting and beyond. Read More ›

In a phase 3 trial, nivolumab combined with cabozantinib improved progression-free survival and overall survival versus sunitinib as first-line therapy. Read More ›

In a phase 3 trial, lenvatinib combined with pembrolizumab improved progression-free survival versus lenvatinib plus pembrolizumab or sunitinib and improved overall survival compared with sunitinib. Read More ›

In a phase 3 study, adjuvant pembrolizumab after nephrectomy improved disease-free survival versus placebo in patients with high-risk disease. Read More ›

In the phase 3 ASCENT study, Trodelvy was demonstrated to significantly enhance quality of life compared with standard of care in second-line and beyond metastatic triple-negative breast cancer. Read More ›

Patients need to know why they are taking Trodelvy, the indications for which include metastatic triple-negative breast cancer. They should be educated on the benefits of Trodelvy along with potential side effects associated with treatment, including guidance on how they can manage those adverse events. Read More ›

Trodelvy Access Support is a patient access and reimbursement support program that will help you and your patients understand reimbursement and specific coverage guidelines for Trodelvy. Read More ›